Coral Laboratories Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Coral Laboratories şirketinin toplam hissedar öz sermayesi ₹1.8B ve toplam borcu ₹0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₹2.1B ve ₹281.8M dir. Coral Laboratories 'in FAVÖK'ü ₹233.1M faiz karşılama oranı 815 dur. Şirketin ₹277.9M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

₹0

Borç

Faiz karşılama oranı	815x
Nakit	₹277.87m
Eşitlik	₹1.77b
Toplam yükümlülükler	₹281.84m
Toplam varlıklar	₹2.06b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 524506 'nin kısa vadeli varlıkları ( ₹1.5B ) kısa vadeli yükümlülüklerini ( ₹249.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: 524506 şirketinin kısa vadeli varlıkları ( ₹1.5B ) uzun vadeli yükümlülüklerini ( ₹32.8M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 524506 borçsuzdur.

Borcun Azaltılması: 524506 şirketinin 5 yıl önce borç/öz sermaye oranı 1.3% iken borcu yok.

Borç Kapsamı: 524506 un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: 524506 şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Coral Laboratories Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Coral Laboratories Limited to Report Q2, 2025 Results on Nov 14, 2024

Investor sentiment improves as stock rises 16%

Insufficient new directors

Upcoming dividend of ₹2.00 per share

Investor sentiment improves as stock rises 22%

New major risk - Share price stability

Coral Laboratories Limited, Annual General Meeting, Sep 27, 2024

First quarter 2025 earnings released: EPS: ₹24.64 (vs ₹5.16 in 1Q 2024)

Coral Laboratories Limited Announces Cessation of Sheela Kamdar as Independent Director

Coral Laboratories Limited to Report Q1, 2025 Results on Aug 14, 2024

Coral Laboratories Limited Announces Resignation of Ruchi Pipara as Company Secretary and Compliance Officer, with Effect from July 13, 2024

Investor sentiment improves as stock rises 19%

New minor risk - Share price stability

Investor sentiment improves as stock rises 20%

Coral Laboratories Limited to Report Q4, 2024 Results on May 23, 2024

Coral Laboratories Limited Appoints Ruchi Pipara as Company Secretary, Compliance Officer and Key Managerial Personnel

Coral Laboratories Limited Announces Resignation of Shifa Memon as Company Secretary, Compliance Officer and Key Managerial Personnel

Coral Laboratories Limited Appoints Shifa Memon as Company Secretary and Compliance Officer, with Effect from March 9, 2024

Investor sentiment improves as stock rises 16%

Now 20% overvalued

Third quarter 2024 earnings released: EPS: ₹6.04 (vs ₹2.40 in 3Q 2023)

Coral Laboratories Limited to Report Q3, 2024 Results on Feb 14, 2024

Investor sentiment improves as stock rises 17%

Second quarter 2024 earnings released: EPS: ₹16.81 (vs ₹13.70 in 2Q 2023)

New minor risk - Share price stability

Investor sentiment improves as stock rises 26%

Coral Laboratories Limited to Report Q2, 2024 Results on Nov 09, 2023

Coral Laboratories Limited to Report Q1, 2024 Results on Aug 12, 2023

Full year 2023 earnings released: EPS: ₹18.04 (vs ₹25.32 in FY 2022)

Coral Laboratories Limited, Annual General Meeting, Aug 11, 2023

New major risk - Market cap size

Full year 2023 earnings released: EPS: ₹18.04 (vs ₹25.32 in FY 2022)

Coral Laboratories Limited to Report Q4, 2023 Results on May 23, 2023

Third quarter 2023 earnings released: EPS: ₹2.40 (vs ₹0.69 in 3Q 2022)

Coral Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023

Second quarter 2023 earnings released: EPS: ₹13.70 (vs ₹1.26 in 2Q 2022)

Second quarter 2023 earnings released: EPS: ₹13.70 (vs ₹1.26 in 2Q 2022)

Coral Laboratories Limited to Report Q2, 2023 Results on Nov 11, 2022

First quarter 2023 earnings released: EPS: ₹4.44 (vs ₹16.24 in 1Q 2022)

Coral Laboratories Limited, Annual General Meeting, Sep 29, 2022

Full year 2022 earnings released: EPS: ₹25.32 (vs ₹37.94 in FY 2021)

Coral Laboratories Limited to Report Q4, 2022 Results on May 27, 2022

Coral Laboratories Limited Receives Resignation of Sanket Mehta as Independent Director

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Coral Laboratories Limited to Report Q3, 2022 Results on Feb 11, 2022

Investor sentiment deteriorated over the past week

Non-Executive Director Purvi Doshi has left the company

Full year 2021 earnings released: EPS ₹37.94 (vs ₹19.96 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS ₹12.95 (vs ₹6.30 in 3Q 2020)

Investor sentiment improved over the past week

Coral Laboratories Limited to Report Q3, 2021 Results on Feb 11, 2021

New 90-day low: ₹274

New 90-day low: ₹297

New 90-day low: ₹306

Market pulls back on stock over the past week

Coral Laboratories Limited to Report Q2, 2021 Results on Nov 12, 2020

New 90-day high: ₹392

New 90-day high - ₹322

First quarter earnings released

Coral Laboratories Limited to Report Q1, 2021 Results on Sep 04, 2020

Full year earnings released - EPS ₹19.96

New 90-day high - ₹286

New 90-day high - ₹233

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin